ArticleNature medicine2017
An approach to suppress the evolution of resistance in BRAF
Registry-linked trialAbstract read
In one paragraph
Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04203095 (Dynamic Monitor of Serum Chromosomal Instability Detected by UCAD as a Surrogate Biomarker of Treatment Efficacy in PD1 Inhibitor Based Immunotherapy for Lung Cancer Patients), which is not on this map. Cited by 105 papers.
0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dynamic Monitor of Serum Chromosomal Instability Detected by UCAD as a Surrogate Biomarker of Treatment Efficacy in PD1 Inhibitor Based Immunotherapy for Lung Cancer Patients
Who cites it
105 citing papers in PubMed.
- Extrachromosomal DNA in urothelial carcinoma: mechanisms and clinical applications.Nature reviews. Urology · 2026Review
- Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition inBiomolecules · 2026Article
- Targeting extrachromosomal DNA in human cancers.Nature reviews. Drug discovery · 2026Review
- Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer.bioRxiv : the preprint server for biology · 2026Article
- Review
- Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review.Frontiers in pharmacology · 2026Review
- A Darwinian Perspective on Tumor Evolution.International journal of biological sciences · 2026Review
- Efficacy and safety of BRAF-MEK inhibitors in treatment of Chinese patients with papillary craniopharyngioma: A retrospective cohort study.Molecular therapy. Oncology · 2025Article
- Extrachromosomal DNA associates with nuclear condensates and reorganizes chromatin structures to enhance oncogenic transcription.Cancer cell · 2025Article
- The long antisense non-coding RNA HOXA transcript at the distal tip (LncRNA HOTTIP) in health and disease: a comprehensive review and in silico analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Recent advancements in tissue dissociation techniques for cell manufacturing single-cell analysis and downstream processing.Stem cells translational medicine · 2025Review
- Reducing phenotype-structured partial differential equations models of cancer evolution to systems of ordinary differential equations: a generalised moment dynamics approach.Journal of mathematical biology · 2025Article
- Single-cell genome and transcriptome sequencing without upfront whole-genome amplification reveals cell state plasticity of melanoma subclones.Nucleic acids research · 2025Article
- Article
- Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.International journal of molecular sciences · 2024Review
- Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.Current treatment options in oncology · 2024Review
- FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Cancer communications (London, England) · 2024Review
- Integration of scHi-C and scRNA-seq data defines distinct 3D-regulated and biological-context dependent cell subpopulations.Nature communications · 2024Article
- In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFCell reports. Medicine · 2024Article
- Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies.Journal of clinical medicine · 2024Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
23 authors.
Yaohua XueHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA.
Luciano MartelottoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Timour BaslanCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Alberto VidesHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA.
Martha SolomonHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA.
Trang Thi MaiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA.
Neelam ChaudharyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA.
Greg J RielyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Bob T LiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kerry ScottNantOmics, Rockville, Maryland, USA.
Fabiola CechhiNantOmics, Rockville, Maryland, USA.
Ulrika StiernerSahlgrenska Translational Melanoma Group, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.
Kalyani ChadalavadaMolecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sarit SchwartzNantOmics, Rockville, Maryland, USA.
Todd HembroughNantOmics, Rockville, Maryland, USA.
Gouri NanjangudMolecular Cytogenetics Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID http://orcid.org/0000-0002-8547-1957
Michael F BergerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jonas NilssonSahlgrenska Translational Melanoma Group, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.
Scott W LoweCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Neal RosenMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Piro LitoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MWeill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Ventura · 2007 to 2026
$31.2MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MStudies on oncoprotein-induced feedback: Basic and therapeutic implicationsR35CA210085 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSEN, NEAL · 2016 to 2022
$7.3MElucidating the regulation of mitosis by BRAF V600E in lung cancerK08CA191082 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LITO, PIRO · 2015 to 2019
$872kNCI NIH HHS K08 CA191082NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA210085NIGMS NIH HHS T32 GM007739NIH HHS U54 OD020355
Abstract
The principles that govern the evolution of tumors exposed to targeted therapy are poorly understood. Here we modeled the selection and propagation of an amplification in the BRAF oncogene (BRAF
Indexed as
AdenocarcinomaAdenocarcinoma of LungAdultAgedAnimalsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarboplatinCisplatinDrug Resistance, NeoplasmExtracellular Signal-Regulated MAP KinasesFemaleHumansIn Situ Hybridization, FluorescenceLung NeoplasmsMaleBevacizumabBRAF protein, humanCarboplatinCisplatinExtracellular Signal-Regulated MAP KinasesMitogen-Activated Protein Kinase KinasesPemetrexedProtein Kinase InhibitorsProto-Oncogene Proteins B-rafraf Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04203095ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.